exRNAdisease

General Information

Database ID:

exR0087750

RNA Name:

hsa-miR-1323

RNA Type:

miRNA

Chromosome:

chr19

Starnd:

Coordinate:

Start Site(bp):

53671978

End Site(bp):

53671999

External Links:

Disease Information

Disease Name:	Breast Cancer
Disease Category:	Cancers
MeSH ID:	D001943
Type:	Neoplasms/Breast Neoplasms
Alias:	Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID:	GSE101841
Description:	Serum microRNA profile of Her2 positive metastatic breast cancer patients
Experimental Design:	Trastuzumab therapy
Case Disease Type:	Breast Cancer
Case Disease SubType:	HER2 positive metastatic breast cancer
Case Sample:	Breast Cancer Trastuzumab resistant
Control Sample:	Trastuzumab sensitive
Number of Case:	42
Number of Control:	61
Number of Samples:	103

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
ABCC5	chr3	183919934	184017939	-
CAMTA1	chr1	6785454	7769706	+
CDK6	chr7	92604921	92836594	-
CDKN1B	chr12	12715058	12722369	+
CELSR2	chr1	109249539	109275751	+
DCAF7	chr17	63550477	63594279	+
NFAT5	chr16	69565094	69704666	+
PLEKHM1	chr17	45435900	45490749	-
PPP1R3C	chr10	91628442	91633071	-
RAB8A	chr19	16111889	16134234	+
ZNF618	chr9	113876282	114056591	+

miRNA targets:

circRNA targets:

circRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa_circ_0000712	chr16	68208276	68225678	+
hsa_circ_0000943	chr19	47421744	47440665	+
hsa_circ_0001151	chr20	35236117	35236221	+

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC016876.2	chr17	7581964	7584086	-
AC022167.2	chr16	8848105	8860456	+
FGD5-AS1	chr3	14920347	14948424	-
GAS5	chr1	173858559	173868882	-
LINC00662	chr19	27681072	27794005	-
MALAT1	chr11	65497688	65506516	+
MCM3AP-AS1	chr21	46229196	46259390	+
MIR17HG	chr13	91347820	91354579	+
NEAT1	chr11	65422774	65445540	+
NUTM2A-AS1	chr10	87201647	87342612	-
OIP5-AS1	chr15	41283990	41309737	+
SNHG15	chr7	44983023	44986961	-
TUG1	chr22	30969245	30979395	+
ZFAS1	chr20	49278178	49299600	+

Display:

Experiment Detail

GEO ID:	GSE101841
Sample Source:	Blood
Source Fraction:	Serum
Platform:	GPL23138
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	1808
Sample treatment protocol:	NA
RNA Extract protocol:	Total RNA was extracted from 103 samples with the Plasma RNA Purification Mini Kit (51000, NorgenBiotek Corporation, Canada), following manufacturer's instructions.
RNA library preparation protocol:	Total RNA extracted from 600ul serum was employed with 100 nmol/L of pCp-DY647 and 15 Units of T4 RNA ligase in a total reaction volume of 20 ul at 16°C overnight.

Reference

PMID:	29691399
Title:	A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Author:	Li H, Liu J, Chen J, Wang H, Yang L, Chen F, Fan S, Wang J, Shao B, Yin D, Zeng M, Li M, Li J, Su F, Liu Q, Yao H, Su S, Song E
Journal:	Nat Commun. 2018 Apr 24;9(1):1614.
Description:	MicroRNAs (miRNAs) have been used to predict therapeutic effects for various cancers, but whether miRNAs can serve as biomarkers for HER2+ metastatic breast cancer (MBC) patients remains unclear.